Optimizing FLT3 Inhibitor Monotherapy in Acute Myeloid Leukemia
December 27, 2017
Acute myeloid leukemia (AML) therapy is guided mainly by cytogenetic profile, such as chromosomal duplication or deletion, and molecular mutations. FLT3 mutations are the most common genetic abnormalities detected in patients with AML and are usually associated with a high relapse rate and short overall survival. Given the dismal outcomes in patients with FLT3-mutant AML, a great effort has been underway over the last several years to develop clinically effective FLT3 inhibitors.